Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 119 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sodium Valproate Clear all
Completed Phase 2Phase 3 Interventional

Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms

NCT00202514
View directory record Official record
Conditions
Alcoholism, Alcohol Related Disorders, Mood Disorders
Interventions
divalproex sodium extended release
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 7, 2009 · Synced Sep 18, 2026, 2:48 AM EDT
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Results available

Valproate in Dementia (VALID)

NCT00071721
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Valproate, Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
46
States / cities
Sun City, Arizona • Tucson, Arizona • Irvine, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 18, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

NCT01552434
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Interventions
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
Biological · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 18, 2026, 2:48 AM EDT
Active, not recruiting Phase 2 Interventional

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

NCT02068586
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma, Stage IIA Intraocular Melanoma, Stage IIB Intraocular Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIC Intraocular Melanoma, Stage I Uveal Melanoma AJCC V7, Stage II Uveal Melanoma AJCC V7, Stage III Uveal Melanoma AJCC V7
Interventions
Sunitinib, Valproic Acid, Sunitinib Malate, Sunitinib Malate + Valproic Acid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Bipolar I Disorder

NCT00257972
View directory record Official record
Conditions
Bipolar Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
20
States / cities
Little Rock, Arkansas • Riverside, California • Deerfield Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 18, 2026, 2:48 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

NCT05431595
View directory record Official record
Conditions
Delirium, Epileptics, Neuroleptics
Interventions
Haloperidol, Chlorpromazine, Valproate, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional

An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder

NCT00060905
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium (Depakote ER)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
18
States / cities
Cerritos, California • Torrance, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2006 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

NCT00513162
View directory record Official record
Conditions
Neuroectodermal Tumor, Brain Metastases, Advanced Cancer
Interventions
Valproate, Etoposide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

NCT00073164
View directory record Official record
Conditions
Schizophrenia
Interventions
Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
35
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2006 · Synced Sep 18, 2026, 2:48 AM EDT
Withdrawn Phase 1 Interventional

Valproic Acid in Childhood Progressive Brain Tumors

NCT01861990
View directory record Official record
Conditions
Pediatric Brain Tumor, Glioma, Anaplastic Astrocytoma, Medulloblastoma, Glioblastoma
Interventions
Valproic Acid
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
1 Year and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 18, 2026, 2:48 AM EDT
Terminated Phase 4 Interventional Results available

Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU

NCT02343575
View directory record Official record
Conditions
Hyperactive Delirium, Mixed Delirium
Interventions
Valproic Acid, Placebo, Haloperidol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Results available

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

NCT00176202
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium, risperidone
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
10 Years to 20 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 18, 2026, 2:48 AM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional

A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.

NCT00195754
View directory record Official record
Conditions
Migraines
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2007 · Synced Sep 18, 2026, 2:48 AM EDT
Not listed Phase 1 Interventional

A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets

NCT01898676
View directory record Official record
Conditions
Epilepsy
Interventions
Divalproex Sodium Extended-release 250mg, DEPAKOTE 250mg
Drug
Lead sponsor
Vince & Associates Clinical Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

NCT00648076
View directory record Official record
Conditions
Healthy
Interventions
Divalproex Sodium Extended-Release Tablets 500 mg, Depakote ER® Tablets 500 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma

NCT00879437
View directory record Official record
Conditions
Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Valproic acid, Bevacizumab, Radiation therapy
Drug · Radiation
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
6
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Decision-Making in Bipolar Disorder

NCT01463111
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Valproate, Lamotrigine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions

NCT00834639
View directory record Official record
Conditions
Healthy
Interventions
divalproex sodium, Depakote®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional

Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents

NCT00195767
View directory record Official record
Conditions
Bipolar I Disorder, Manic or Mixed
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
10 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism

NCT00211757
View directory record Official record
Conditions
Autism
Interventions
Divalproex sodium, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 18, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913
View directory record Official record
Conditions
Mania, Bipolar Disorder
Interventions
Xanomeline/Trospium Chloride, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 18, 2026, 2:48 AM EDT
Completed No phase listed Observational Results available

Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?

NCT01231646
View directory record Official record
Conditions
Epilepsy, Psychiatric or Mood Diseases or Conditions
Interventions
No intervention
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 18, 2026, 2:48 AM EDT